Project Grant R01DA064212
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $703,675 Project Grant (CFDA 93.279) to the University of North Carolina at Chapel Hill (UNC-CH) for the project "Transcriptional Inactivation of the CNS HIV Reservoir with Tat-Targeting Lipid Nanoparticles." This grant aims to develop lipid nanoparticles containing gene-editing tools that can inactivate the HIV Tat gene in microglial cells, the primary HIV reservoir in the central...
- This $418,625 Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to Drexel University supports research to develop a novel approach using RNA interference (RNAi) to silence HIV transcription in myeloid cells. The goal is to functionally eliminate the HIV reservoir in the central nervous system by inducing a stable heterochromatic state to block proviral transcription and production of new virions in chronically infected...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,825,990 Project Grant to the Texas Biomedical Research Institute (doing business as Southwest Foundation for Biomedical Research) to use focused ultrasound-stimulated blood-brain barrier opening (FUS-BBBO) to deliver long-acting combination antiretroviral therapy (cART) drugs and anti-inflammatory treatments to the basal ganglia and hippocampus regions of the brain. This...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $687,416 Project Grant to the J. David Gladstone Institutes in San Francisco, California. The grant is for a research project titled "Targeted Small Molecule Recruitment to Suppress the HIV Transcriptionally Active Reservoir" and runs from May 15, 2025 to March 31, 2030. The key objectives of this research project are to develop therapeutically effective...
- This federal Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 to the Regents of the University of California at Riverside to investigate the role of the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis in promoting HIV-1 persistence and brain injury in individuals living with HIV who use methamphetamine. The 5-year project, starting June 1, 2025, aims to determine...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $2,331,737 to the University of California, San Francisco (UCSF) to conduct research on the impact of methamphetamine use on immune dysfunction and HIV reservoir transcription among people with HIV receiving antiretroviral therapy. The research will utilize in vivo imaging and post-mortem studies to examine how methamphetamine use...
- The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1 project grant to the J. David Gladstone Institutes. The grant aims to establish a novel mouse model for studying the impact of HIV and addictive substances on the central nervous system. Specifically, the project will develop a chimeric mouse model with human microglia, neurons, and astrocytes derived from induced pluripotent stem cells. This model will be used to...
- This $616,372 federal Project Grant was awarded on July 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to identify neuronal, glial, and neural stem/progenitor cell transposable element (TE) transcriptional and epigenetic gene regulatory states involved in SIV, antiretroviral therapy, and cannabinoid exposure in a non-human primate model. Additionally, the research aims to identify TE expression...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $887,626 to the University of Miami to conduct research focused on preventing immune responses towards adeno-associated virus (AAV)-delivered anti-HIV antibodies. The project aims to explore two strategies to induce tolerance and prevent anti-drug antibody (ADA) formation in response to AAV-mediated gene therapy delivering broadly neutralizing HIV...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $558,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Massachusetts Institute of Technology (MIT) for the project "Integration and Validation of Single-Cell Neuronal and Immune Molecular Responses in SUD and HIV". The project aims to uncover the genetic and molecular mechanisms driving the interactions between HIV, neuropsychiatric, and...